New Zealand’s Commerce Commission has announced a probe into the nation’s pharmaceutical industry. While the Commission had originally ordered changes on the Community Pharmacy Services Agreement last July, the authority is now looking into whether certain clauses in that agreement were created in an attempt to fix prices of prescription medications. According to reports, the agreement prohibited the act of discounting prescription drugs at pharmacies. When the clause was contested by a pharmacy owner, the Commission removed the clauses last December on the basis the agreement was anticompetitive. Now, according to the authority, DHB Shared Services, which added the clauses, as well as the organizations that supported it, are now under investigation.
Full Content: Radio NZ
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Japan’s Prime Minister Criticizes US Block on Nippon Steel-US Steel Deal
Feb 17, 2025 by
CPI
UAE Cabinet Announces New Merger Control Filing Thresholds Effective March 2025
Feb 17, 2025 by
CPI
UK Regulator Warns Topps Tiles Acquisition Could Hurt Competition
Feb 17, 2025 by
CPI
FTC Chair Andrew Ferguson Backs Trump’s Authority to Remove Commissioners
Feb 17, 2025 by
CPI
South Korea Suspends Downloads of Chinese AI App DeepSeek Over Data Privacy Concerns
Feb 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon